Today's journal articles

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy

Previous Journal Entries

Paraoxonase 1: A better atherosclerotic risk predictor than HDL in type 2 diabetes mellitus.

1,4 - Benzothiazine ATP - sensitive potassium channel openers: modifications at the C - 2 and C - 6 positions.

Discovery of a highly potent, nonabsorbable apical sodium - dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes.

COMP-Angiopoietin-1 Promotes Cavernous Angiogenesis in a Type 2 Diabetic Rat Model.

Administration of IL-1 Trap prolongs survival of transplanted pancreatic islets to type 1 diabetic NOD mice.

Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey.

Increases in inflammatory mediators in DRG implicate in the pathogenesis of painful neuropathy in Type 2 diabetes.

Superior renoprotective effects of the combination of breviscapine with enalapril and its mechanism in diabetic rats.

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes.

Rosiglitazone Treatment of Type 2 Diabetic db/db Mice Attenuates Urinary Albumin and Angiotensin Converting Enzyme 2 Excretion.

Role of the P2Y13 receptor in the differentiation of bone marrow stromal cells into osteoblasts and adipocytes.

DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy.

Study Design and Rationale of a Dose-Ranging Trial of LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy.

A comprehensive analysis of adiponectin QTLs using SNP association, SNP cis-effects on peripheral blood gene expression and gene expression correlation identified novel metabolic syndrome (MetS) genes with potential role in carcinogenesis and systemic inflammation.

Dual PPAR α / γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia.

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-l).

Efficacy And Safety Of Lixisenatide Once Daily Versus Placebo In Type 2 Diabetes Insufficiently Controlled On Pioglitazone (Getgoal-P).

Omentin-1 Stimulates Human Osteoblast Proliferation through PI3K/Akt Signal Pathway.

Evaluating Second-Line Treatment Options for Type 2 Diabetes: Focus on Secondary Effects of GLP-1 Agonists and DPP-4 Inhibitors.

Blockage of Peripheral NPY Y1 and Y2 Receptors Modulates Barorefex Sensitivity of Diabetic Rats.

Today's News Items

Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States

New Data Showed LIVALO® (pitavastatin) 4 mg had Neutral Effects on Fasting Serum Glucose and HbA1c Levels in HIV-infected Adults with Dyslipidemia

Training Courses & Meetings

No events listed

Previous News Items

pSivida Corp. Announces UK\'s NICE Says Yes to ILUVIEN® in Some Patients with Diabetic Macular Edema in New Draft Guidance

MannKind Completes Phase 3 Clinical Study of AFREZZA in Patients with Type 2 Diabetes

---

For faster discovery, automatically organize PubMed results into categories